Programme
Download the abstractbook here (high resolution, 36 mb). Or with a low resolution here (4 mb).
Sunday, 15.09.2013 |
||
09:00-11:00 | Set-up of exhibition | |
11:00 | Welcome coffee, tea or soft drinks for the participants are available | |
11:00 | Registration open | |
13:00-13:15 | Welcome Addresses | |
Session I - International Activities, Disease Models & Human-on-a-chip |
||
13:15-13:35 | Hajime Kojima, National Institute of Health Sciences, JP-Tokyo Japanese project “ARCH-Tox” for the future chemicals management policy: research and development of in vitro and in vivo assays for internationally leading hazard assessment and test methods |
|
13:35-13:55 | Horst Spielmann, Freie Universität Berlin, DE-Berlin Peer review panel evaluation of the ROS Photosafety Assay (click to download e presentation as pdf, 1,64 MB) |
|
13:55-14:15 | Mario Fabri, University of Cologne, DE-Cologne Vitamin D-dependent antimicrobial pathways in human macrophages |
|
14:15-14:35 | Günther Weindl, Freie Universität Berlin, DE-Berlin Increased cutaneous absorption reflects impaired barrier function of reconstructed skin models mimicking keratinisation disorders |
|
14:35-14:55 | Eva-Maria Materne, TU Berlin, DE-Berlin A multi-organ-chip platform for long-term maintenance and substance testing of human tissue co-culture (click to download the presentation as pdf, 7,16 MB) |
|
14:55-15:15 | Dmitry Sakharov, Scientific Research Centre Bioclinicum, RU-Moscow A dynamic multi-organ-chip containing enterocytes and hepatocytes for the absorption of orally administered drugs prediction and substance toxicity testing |
|
15:15-16:30 | Poster session I + coffee break and exhibition Chairs: Eleonore Haltner-Ukomadu (DE) & Tuula Heinonen (SF) |
|
16:30-17:00 | Horst Spielmann, Freie Universität Berlin, DE-Berlin Willi Halle Memorial Lecture (click to download the presentation as pdf, 3,38 MB) |
|
Session II – 3Rs go 3D Chairs: Helena Kandarova (SK) & Günter Weindl |
||
17:00-17:30 | Ellen Fritsche, Leibniz Research Institute of Environmental Medicine, DE-Düsseldorf Human Neural Progenitor Cell (hNPC) Aging is mimicked by 3D Cultures in vitro: an ‘Adverse Outcome Pathway’ gains importance at susceptible life stages (click to download the presentation as pdf, 2,8 MB) |
|
17:30-17:45 | Jens Kelm, InSphero AG, CH-Zürich 3-dimensional organotypic in vitro model systems for liver, cardiac and neuro safety assessment |
|
17:45-18:00 | Silvia Angeloni, CSEM SA, CH-Neuchâtel Blood-brain tumor and air-blood tissue barrier: two examples of how BioMEMS can improve the relevance of co-cultured in-vitro models of biological barriers |
|
18:00-18:15 | Frederique van Acker, TNO Triskelion, NL-Zeist Cerium oxide nanoparticles air exposure: a comparison study using a human 3D airway model, A549 and BEAS-2B cell lines |
|
18:15-18:30 | Nicky Slawny, 3D Biomatrix, Inc., US-Ann Arbor 3D spheroid cell cultures as models in drug discovery |
|
18:30-18:45 | Martha Liley. CSEM SA, CH-Neuchâtel Towards replacing in vivo tests of dental and orthopedic implants |
|
19:15-20:45 | Annual general assembly of EUSAAT | |
Monday, 16.09.2013 - special day( = session III of the 18th European Congress on Alternatives to Animal Testing)ESNATS CONFERENCE - Preliminary Programme "Use of Human Embryonic Stem Cells for Novel Toxicity Testing
|
||
09:00-09:10 | Horst Spielmann, President of EUSAAT, Freie Universitaet Berlin, DE-Berlin Opening address |
|
09:10-09:20 | Jürgen Hescheler, Coordinator of ESNATS, University of Cologne, DE-Cologne Overview of the ESNATS project |
|
09:20-10:00 | Marcel Leist, University of Konstanz, DE-Konstanz The ESNATS hESC-based toxicity test battery |
|
10:00-10:40 | Jan Hengstler, IFADO, DE-Dortmund The ESNATS hESC-based toxicity biomarker identification study |
|
10:40-11:00 | Jan Hengstler, IFADO, DE-Dortmund Hepatocyte in vitro systems to study metabolism: stem cell derived hepatocytes as an alternative to primary hepatocytes |
|
11:00-11:15 | Coffee break | |
11:15-11:30 | Joery de Kock, Vrije Universiteit Brussels, BE-Brussels hSKP-derived hepatocytes for toxicity testing |
|
11:30-11:50 | Sieto Bosgra, TNO, NL-Utrecht In vitro-in vivo extrapolation of prenatal (neuro)toxicity assay data by PBPK modeling |
|
11:50-12:10 | Agapios Sachinidis, University of Cologne, DE-Cologne Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells |
|
12:10-12:30 | Karl-Heinz Krause, University of Geneva, CH-Geneva Pluripotent stem cell-derived engineered neural tissues: what’s new? |
|
12:30-13:45 | Lunch and posters | |
13:45-14:30 | First panel discussion (chair: Thomas Hartung, CAAT, US Baltimore) How can the ESNATS data be used to define mechanisms of action and/or AOPs |
|
14:30-15:00 | Aldert Piersma, RIVM, NL-Bilthoven Enhancing the readout of the embryonic stem cell test with molecular approaches |
|
15:00-15:30 | Ellen Fritsche, Leibniz Research Institute for Environmental Medicine, DE-Duesseldorf Signaling pathways in human neural assays (title to be confirmed) |
|
15:30-16:00 | Robert Kavlock, US Environmental Protection Agency, US-Washington Transforming the Conduct of Toxicology in the US: the Tox21 Program |
|
16:00-16:30 | Coffee break and posters | |
16:30-17:00 | Thomas Knudsen, US Environmental Protection Agency, US-Research Triangle Park Predictive models and computational embryology |
|
17:00-17:30 | Beatriz Silva-Lima, EPAA stem cell group, BE-Brussels EPAA calls for a “Stem Cells in Safety Testing” forum to keep fluent communication |
|
17:30-18:00 | Jos Kleinjans, University of Maastricht, NL-Maastricht Data infrastructure for chemical safety |
|
18:00-18:45 | Second panel discussion (chair: Michael Schwarz, University of Tuebingen, DE-Tuebingen) How can the ESNATS assays be applicable in companies/regulatory toxicology and what are necessary future developments |
|
18:45-20:00 | Continued discussion and poster session | |
20:00 | Dinner and social evening (at the congress venue) ESNATS & EUSAAT welcome you! |
|
Tuesday, 17.09.2013 |
||
Session IV – EU Dir 2010/63 & Ethical & legal Aspects Chairs: Susanna Louhimies (BE) & Ursula Sauer (DE) |
||
09:00-09:30 | Susanna Louhimies, The European Commission, BE-Brussels Directive 2010/63/EU: Overview of the work of Commission Expert Working Groups on an EU Framework for Education and Training and on Project Evaluation (click to download the presentation as pdf, 1,29 MB) |
|
09:30-10:00 | Katharina Kluge, Federal Ministry of Food, Agriculture and Consumer Protection, DE-Bonn Implementation of Directive 2010/63/EU into German law |
|
10:00-10:15 | Ursula G. Sauer, Scientific Consultancy - Animal Welfare, DE-Neubiberg Ethical review of projects involving non-human primates funded under the European Union’s 7th Research Framework Programme |
|
10:15-10:30 | Norbert Alzmann, Messerli Research Institute, AT-Vienna A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation (click to download the presentation as pdf, 0,44 MB) |
|
10:30-10:45 | Marie-Jeanne Schiffelers, Utrecht University School of Governance, NL-Utrecht Factors influencing regulatory acceptance and use of 3R models & strategies to improve this process: The case of the EOGRTS |
|
10:45-11:00 | Mangala Gunatilake, University of Colombo, LK-Colombo Steps taken to implement 3Rs concept in research using animals in Sri Lanka (click to download the presentation as pdf, 0,83 MB) |
|
|
||
11:00-11:40 | Coffee break, posters and exhibition | |
Session V – Consequences of the 2013 EU Marketing Ban for Cosmetics & NanoTox Chairs: Dagmar Jirova (CZ) & Klaus Schröder (AT) |
||
11:40-11:55 | Gamze Ates, Vrije Universiteit Brussel, BE-Brussels Retrospective analysis of the mutagenicity/genotoxicity data of the cosmetic ingredients present on the Annexes of the Cosmetic EU legislation |
|
11:55-12:10 | Helena Kandarova, MatTek In Vitro Life Science Laboratories, SK-Bratislava Ability of the reconstructed human tissue models to correctly predict phototoxicity and photopotency of topically applied substances and formulations: Review of available data |
|
12:10-12:25 | Martin Paparella, Environment Agency Austria, AT-Vienna Uncertainty of testing methods – What do we (want to) know? (click to download the presentation as pdf, 0,23 MB) |
|
12:25-12:40 | Katy Taylor, BUAV/ECEAE, UK-London The ADAPT principles for regulatory authorities (click to download the presentation as pdf, 0,67 MB) |
|
12:40-12:55 | Stefanie Schindler, Animalfree Research, CH-Bern Mind the gap - developing and implementing integrated testing strategies into nanotoxicology (click to download the presentation as pdf, 0,25 MB) |
|
12:55-13:10 | Cornelia Loos, University of Ulm, DE-Ulm The chick chorioallantoic membrane (CAM) assay as a model for the development of antitumor nanotherapeutics |
|
|
||
13:10-14:30 |
Lunchtime poster session - poster session II |
|
Session VI - Specific Endpoints of Toxicity - Session I (part I) Chairs: Rodger Curren (US) & Robert Landsiedel (DE) |
||
14:30-14:50 | Robert Landsiedel, BASF SE, DE-Ludwigshafen Hurdles during the development and application of alternative methods: a perspective from the chemical industry |
|
14:50-15:05 | Judith Madden, Liverpool John Moores University, UK-Liverpool Modelling local and systemic toxicity: Incorporation of in silico predictions in the development of adverse outcome pathways (click to download the presentation as pdf, 0,69 MB) |
|
15:05-15:20 | Jan Willem Van der Laan, Medicines Evaluation Board, NL-Utrecht Pharmacology and Carcinogenicity. Predicitivity as a possibility to reduce the number of carcinogenicity studies |
|
15:20-15:35 | Katherina Sewald, Fraunhofer ITEM, DE-Hannover Pre-validation of the ex vivo model PCLS for the prediction of acute inhalation toxicity |
|
15:35-15:50 | Rodger Curren, Institute for In Vitro Sciences Inc. (IIVS), US-Gaithersburg, MD Further refinement of the Reconstructed Skin Micronucleus Genotoxicity Assay (RSMN) |
|
15:50-16:05 | TzuTzuy Ramirez Hernandez, BASF SE, DE-Ludwigshafen Inter-laboratory validation of the Yeast Estrogen and Yeast Androgen Screens for identification of Endocrine Active Substances |
|
|
||
16:05-16:45 | Coffee break, posters and exhibition | |
Session VII - Tox21 (TT21C) & Specific Endpoints of Toxicity (part II) Chairs: Carole Mathis (CH) & Roman Kolar (DE) |
||
16:45-17:00 | Robert A Coleman, Safer Medicines Trust, UK-London Humanizing toxicity testing in the 21st century: Who should be responsible for introduction of human biology-based tests into regulatory process? (click to download the presentation as pdf, 0,21 MB) |
|
17:00-17:15 | Carl Westmoreland, Unilever, UK-Bedford 21st century safety science and non animal approaches at Unilever (click to download the presentation as pdf, 2,09 MB) |
|
17:15-17:30 | Marcel Leist, Univ. of Konstanz, DE-Konstanz Use of transcriptome profiling in stem cell based test systems for reproductive toxicity |
|
17:30-17:45 | Julia Hoeng, Philip Morris International, CH- Neuchâtel Assessing the effects of repeated cigarette smoke exposure using human organotypic systems reproducing the respiratory tract in vitro |
|
17:45-18:00 | Anne Krug, Univ. of Konstanz, DE-Konstanz Integrating transcriptomics and metabolomics to identify pathways of toxicity of the parkinsonian toxin MPP+ |
|
18:30 | Departure for the social evening | |
19:00 | Social evening | |
|
||
Wednesday, 18.09.2013 |
||
Session VIII - Implementing Alternatives into Basic Research Chairs:Tzutzuy Ramirez-Hernandez (DE) & Tuula Heinonen (SF) |
||
09:00-09:15 | Gerhard Püschel, University of Potsdam, DE-Potsdam Cell culture-based in vitro method for determining the activity of the botulinum toxin |
|
09:15-09:30 | Karin Schütze, CellTool GmbH, DE-Bernried Novel laser-based identification of cancer cells and monitoring of cell-agent interactions (click to download the presentation as pdf, 4,27 MB) |
|
09:30-09:45 | Theresia Licka, University of Veterinary Medicine, AT-Vienna Research in perfused limbs successfully replaces induction of laminitis in live horses |
|
09:45-10:00 | Günther Weindl, Freie Universität Berlin, DE-Berlin Phase I biotransformation of testosterone by human skin and reconstructed skin tissues |
|
10:00-10:15 | Candida Nastrucci, Tor Vergata University, IT-Rome The alternatives to animal experiments in basic research and education: Status and possibilities in the EU |
|
10:15-10:30 | Johannes Grillari, VIBT – BOKU, AT-Vienna Immortalized primary-like human cells as novel model systems in nephrotoxicity |
|
sponsor
|
||
10:30-11:00 | Coffee break, posters and exhibition | |
Session IX - Drugs, Vaccines & EU FP7 Projects Chairs: Horst Spielmann (DE) & Eleonore Haltner-Ukomadu (DE) |
||
11:00-11:18 | Maren Bernau, Livestock Center Oberschleissheim, DE- Oberschleissheim Magnetic resonance imaging as an alternative method in safety-testing of veterinary vaccines – preliminary results in pigs |
|
11:18-11:36 | Otmar Schmid, Comprehensive Pneumology Center & Helmholtz Zentrum München, DE-Neuherberg New perspectives for realistic and efficient in vitro screening for inhalable drugs |
|
11:36-11:54 | Jiu Jia, Department of Clinical Pharmacology, University Medicine, Greifswald, Germany Use of in vitro cell assays and noninvasive imaging techniques to reduce animal experiments in drug development (click to download the presentation as pdf, 1,32 MB) |
|
11:54-12:12 | Francois Busquet, CAAT EU, BE-Brussels The CAAT EU policy program in Brussels (click to download the presentation as pdf, 2,46 MB) |
|
12:12-12:30 | Sunniva Förster, University of Konstanz, DE-Konstanz Development and application of an algorithm to determine statistically-valid non-cytotoxic concentrations from imperfect in vitro cytotoxicity data sets |
|
12:30-12:40 | Closing remarks | |
12:40 | End of the 18th European Congress on Alternatives to Animal Testing | |
13:00 | Start of the post congress EUSAAT 2013 Training Course | |